Learn More
Today's smartphone operating systems frequently fail to provide users with adequate control over and visibility into how third-party applications use their privacy-sensitive data. We address these shortcomings with TaintDroid, an efficient, systemwide dynamic taint tracking and analysis system capable of simultaneously tracking multiple sources of sensitive(More)
  • Edward B Curtis, James A Morrow, Sara A Beavers, Thaddeus J Edens, Jeffrey E Eldridge, Troy B Holly +93 others
  • 2014
Preface This book is the result of an accumulation of work done by the authors and their students over the past twelve years. In each of the years listed, 8-10 students were brought to the University of Washington for a summer REU (Research Experience for Undergraduates) program, supported by a REU Grant from the NSF. We want to thank the NSF for its(More)
BACKGROUND Elevated risk of HIV-1 infection among recipients of an adenovirus serotype 5 (Ad5)-vectored HIV-1 vaccine was previously reported in the Step HIV-1 vaccine efficacy trial. We assessed pre-infection cellular immune responses measured at 4 weeks after the second vaccination to determine their roles in HIV-1 infection susceptibility among Step(More)
BACKGROUND Observational data and non-human primate challenge studies suggest that cell-mediated immune responses might provide control of HIV replication. The Step Study directly assessed the efficacy of a cell-mediated immunity vaccine to protect against HIV-1 infection or change in early plasma HIV-1 levels. METHODS We undertook a double-blind, phase(More)
BACKGROUND In Thailand, phase 1/2 trials of monovalent subtype B and bivalent subtype B/E (CRF01_AE) recombinant glycoprotein 120 human immunodeficiency virus type 1 (HIV-1) vaccines were successfully conducted from 1995 to 1998, prompting the first HIV-1 vaccine efficacy trial in Asia. METHODS This randomized, double-blind, placebo-controlled efficacy(More)
BACKGROUND A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pro, and membrane-linked gp120 (vCP1521), combined with a bivalent gp120 protein boost (AIDSVAX B/E), provided modest protection against HIV-1 infection in a community-based population in Thailand (RV144 trial). No protection was observed in Thai injection(More)
As more services have come to rely on sensor data such as audio and photos collected by mobile phone users, verifying the authenticity of this data has become critical for service correctness. At the same time, clients require the flexibility to tradeoff the fidelity of the data they contribute for resource efficiency or privacy. This paper describes(More)
To help to design vaccines for acquired immune deficiency syndrome that protect broadly against many genetic variants of the human immunodeficiency virus, the mutation rates at 118 positions in HIV amino-acid sequences of subtype C versus those of subtype B were compared. The false discovery rate (FDR) multiple-comparisons procedure can be used to determine(More)
gamma-Aminobutyric acid (GABA) depolarizes in a dose-dependent manner approximately one-third of all immunologically identified oligodendrocytes in cultures of mouse spinal cord. Measurements of [K+]o indicate that the response to GABA is not due to K+ released from active neurons. The depolarization is not accompanied by a change in cell input resistance.(More)
The world's first efficacy trial of a preventive HIV vaccine was completed in 2003. Study participants who became HIV infected were followed for 2 years and monitored for HIV viral load and initiation of antiretroviral therapy (ART). In order to determine if vaccination may have altered HIV progression in persons who acquired HIV, a pre-specified objective(More)